Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss

More on GLP-1 and incretin signalling

• Semaglutide may protect kidneys by reducing vascular resistance

  Nature Medicine · 4 Oct 2026

  

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026

• GLP-1 agonists linked to lower dementia risk after COVID-19

  Drug Design, Development and Therapy · 5 Oct 2026

  

• GLP-1 receptor agonists link to lower stroke and Alzheimer risk

  Neurology Genetics · 4 Oct 2026